Multi-omics analysis linking zonular laxity and primary angle‑closure glaucoma
The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis
It will test whether molecular differences in eye fluid, blood, and the anterior lens capsule link zonular laxity to primary angle‑closure glaucoma in adults aged 50 and older.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Zhongnan Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT07539675 on ClinicalTrials.gov |
What this trial studies
This is an observational, multi-omics study comparing PACG patients with intraoperatively confirmed zonular laxity, PACG patients with normal zonules, and age- and sex-matched cataract controls. Researchers will collect aqueous humor, blood, and anterior lens capsule samples during surgery and perform genomic, proteomic, and other molecular analyses. Differentially expressed molecules will be identified and integrated to build potential mechanistic networks explaining how zonular abnormalities may contribute to PACG pathogenesis. No additional experimental interventions are performed beyond standard surgical procedures.
Who should consider this trial
Good fit: Adults aged 50 or older with a clinical diagnosis of primary angle‑closure glaucoma who are undergoing glaucoma surgery with intraoperative confirmation of either significant zonular laxity or normal zonular morphology, or age‑ and sex‑matched cataract patients without glaucoma for the control group.
Not a fit: Patients with secondary glaucoma, prior intraocular surgery, systemic diseases affecting zonules, other severe ocular diseases, or long‑term use of medications that alter connective tissue metabolism are excluded and unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the work could reveal molecular mechanisms or biomarkers that help diagnose or guide new treatments for PACG linked to zonular laxity.
How similar studies have performed: Some multi-omics work in glaucoma has identified molecular signatures, but applying multi-omics specifically to zonular laxity in PACG is largely novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically diagnosed with primary angle-closure glaucoma (PACG) * Aged ≥ 50 years, no gender restriction * Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity * Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology * Control group: age- and sex-matched with case groups; clinically diagnosed with age-related cataract; normal anterior chamber depth and angle; no history or signs of glaucoma; undergoing cataract surgery Exclusion Criteria: * Secondary glaucoma * History of previous intraocular surgery * Systemic diseases that can cause abnormal ocular zonules * Other severe ocular diseases * Long-term use of medications affecting connective tissue metabolism
Where this trial is running
Wuhan, Hubei
- Zhongnan Hospital of Wuhan University — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Xuetian Yu, student — The Second Clinical College of Wuhan University
- Study coordinator: Min Ke, doctor
- Email: Keminyk@163.com
- Phone: 18672395959
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.